The C-suite shuf­fle: On­copep­tides, Zymeworks re­place ex­ecs to start 2023

Two biotechs are shuf­fling their C-suites as the cal­en­dar turns to the new year: On­copep­tides and Zymeworks.

On­copep­tides an­nounced Wednes­day that it’s re­plac­ing CEO Jakob Lind­berg with Mon­i­ca Shaw as Lind­berg re­turns to the chief sci­ence po­si­tion. Zymeworks, mean­while, re­moved chief med­ical of­fi­cer Neil Joseph­son with­out nam­ing a re­place­ment. The biotech said Jef­frey Smith, the Alder Bio­Phar­ma­ceu­ti­cals founder who en­gi­neered a $2 bil­lion sale to Lund­beck in 2019, will take over ear­ly R&D.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.